Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Single-minded homolog 1 (SIM1) is a transcription factor of the basic helix-loop-helix-PAS (bHLH-PAS) family, which plays a critical role in embryonic and neural development, especially in the formation and function of the paraventricular nucleus of the hypothalamus[1][2][3][4]. SIM1 functions as a heterodimer with ARNT or ARNT2 to regulate gene expression essential for neurogenesis, energy homeostasis, and feeding behavior[1][2][3][4]. Disruption of SIM1, whether through haploinsufficiency or missense variants, is associated with severe early-onset obesity and syndromes resembling Prader-Willi, primarily due to hyperphagia and dysregulation of hypothalamic circuits controlling energy balance[2][3][4]. It does not currently serve as a direct drug target, but its genetic status is important in the differential diagnosis of syndromic or monogenic obesity.
not applicable (no drugs currently target SIM1 directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Single-minded homolog 1 (SIM1).